2013年4月
Cellular immunotherapy for leukemia
Drug Delivery System
- ,
- 巻
- 28
- 号
- 1
- 開始ページ
- 10
- 終了ページ
- 16
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.2745/dds.28.10
Relapse after chemotherapy is inevitable in the majority of patients with leukemia. Thus, it is necessary to develop novel therapies that have different antileukemic mechanisms. Recent advances in immunology and identification of promising leukemia-associated antigens open the possibilities for eradicating minimal residual diseases by antigen-specific immunotherapy after chemotherapy. Several methods have been pursued as immunotherapies for leukemia: peptide vaccines, granulocyte-macrophage colony stimulating factor-secreting tumor vaccines, dendritic cell vaccines, and adoptive T cell therapy. Whereas immunogenicity and clinical outcomes are improving in these trials, severe adverse events were observed in highly avid engineered T cell therapies, indicating the importance of the balance between effectiveness and side effects in advanced immunotherapy. Such progress in inducing antitumor immune responses, together with strategies to attenuate immunosuppressive factors, will establish immunotherapy as an important armament to combat leukemia.
- リンク情報
- ID情報
-
- DOI : 10.2745/dds.28.10
- ISSN : 0913-5006
- ISSN : 1881-2732
- SCOPUS ID : 84876943053